Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

837
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
837
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

895
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
895
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.5K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

770
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
770

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of dyssynchrony in short-term left ventricular systolic function after iron repletion in patients with heart failure.

Communications medicine·2026
Same author

Circulating Extracellular Vesicles in the Pathogenesis of Heart Failure in Patients With Chronic Kidney Disease.

Circulation·2025
Same author

Meta-analysis and Meta-regression for Uncertain Areas and the Estimation of Possible Benefit of Future Therapies.

European cardiology·2025
Same author

Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.

European heart journal·2025
Same author

Exploring the Relationship Between Sleep Apnea, Myocardial Infarct Size, and Coronary Collaterals in Acute Myocardial Infarction: A Multidisciplinary Study.

Nature and science of sleep·2025
Same author

Does One Size Fits All?

Cardiovascular drugs and therapy·2024
Same journal

GLP-1 Agonists and Risk of Atrial Fibrillation in Non-Dialysis Chronic Kidney Disease.

Cardiovascular drugs and therapy·2026
Same journal

Methodological Considerations in Evaluating Plaque Stabilization in Patients with High Lipoprotein(a).

Cardiovascular drugs and therapy·2026
Same journal

Association of In-Hospital Dapagliflozin Initiation with Favorable left Ventricular Remodeling in Patients with Acute Myocardial Infarction and Heart Failure: A Retrospective Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Impact of Nitric Oxide Metabolites On Early Perioperative Biochemical Changes and Postoperative Complications in High-BMI Patients Undergoing On-Pump CABG: an Exploratory Observational Cohort Study.

Cardiovascular drugs and therapy·2026
Same journal

Comparative Cardiovascular, Lipid, and Safety Effects of Lipid-Modifying Therapies in Diabetes: An Agent-, Class-, and Dose-Level Network Meta-Analysis.

Cardiovascular drugs and therapy·2026
Same journal

Cardiovascular Genetic Epidemiology in the Genome-Wide Era: From Association Discovery to Mechanistic Dissection and Clinical Translation.

Cardiovascular drugs and therapy·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K

Sotagliflozin: Two Birds with One Stone?

Juan Antonio Requena-Ibáñez1, Kristine Mørk Kindberg2,3, Carlos G Santos-Gallego4

  • 1Atherothrombosis Research Unit, Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl., New York, NY, 10029-0310, USA. juanantonio.requenaibanez@mssm.edu.

Cardiovascular Drugs and Therapy
|June 4, 2025
PubMed
Summary
This summary is machine-generated.

Dual SGLT1-2 inhibitors, like sotagliflozin, show promise in reducing major adverse cardiovascular events, including heart attack and stroke, potentially offering greater benefits than SGLT2 inhibitors alone for heart failure patients.

Keywords:
DiabetesHeart failureSGLT1-2 inhibitorsSGLT2 inhibitorsSotagliflozinThrombosis

More Related Videos

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

14.9K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.0K

Related Experiment Videos

Last Updated: Mar 17, 2026

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.8K
A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels
05:31

A Fluorescent Screening Assay for Identifying Modulators of GIRK Channels

Published on: April 24, 2012

14.9K
Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
07:15

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

1.0K

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are established treatments for heart failure (HF), reducing major adverse cardiovascular events (MACE).
  • SGLT2i do not significantly impact atherothrombotic events like myocardial infarction (MI) or stroke.
  • Sotagliflozin is a novel dual inhibitor of SGLT1 and SGLT2.

Purpose of the Study:

  • To compare the cardiovascular benefits of dual SGLT1-2 inhibition versus SGLT2 inhibition alone.
  • To explore the role of SGLT1 in cardiovascular pathophysiology and its potential as a therapeutic target.
  • To evaluate the impact of sotagliflozin on MACE, MI, and stroke.

Main Methods:

  • A comprehensive literature review of studies published within the last five years was performed.
  • Databases searched included PubMed and Scopus.
  • Article selection was based on relevance, methodological quality, and citation impact.

Main Results:

  • SGLT1 and SGLT2 share roles in glucose reabsorption, with SGLT1 also involved in intestinal glucose absorption.
  • SGLT1 is overexpressed in failing hearts, contributing to oxidative stress, cardiomyocyte hypertrophy, and fibrosis.
  • SGLT1 inhibition by sotagliflozin may reverse detrimental metabolic changes in the heart and reduce platelet activation.
  • Sotagliflozin demonstrated reductions in MACE, MI, and stroke, unlike SGLT2i alone.

Conclusions:

  • Dual SGLT1-2 inhibition may provide additional cardiovascular benefits beyond SGLT2 inhibition.
  • Further research is needed to elucidate the distinct clinical impacts of SGLT2i versus SGLT1-2i.
  • Comparative and mechanistic studies are essential, especially in non-diabetic patients with heart failure.